Create a narrative

Glaukos Community

NYSE:GKOS Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 13 Analysts

Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025

Key Takeaways Anticipated launches of iDose TR and Epioxa could significantly boost revenue and strengthen market position in glaucoma and corneal health sectors. International expansion and strategic investments enhance competitive edge, driving long-term growth through improved operational efficiency and market share gains.

US$151.62

FV

40.7% undervalued

26.72%

Revenue growth p.a.

0

0

1

9 days ago